 Home > Pharmaceutical Intermediates > Dermatological Agents > Garenoxacin for Sale > Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections.

Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections. buy - large image1

Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections. buy - image1

Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections. buy - image2

Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections. buy - image3

Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections.

Name: Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections.
Brand: Tianrui
SKU: pr2511131228
Price: 11 USD
Availability: InStock

Unit Price: Get Latest Price 

CAS No.:

194804-75-6

Grade:

Pharmaceutical Grade

Content:

98.5%

Port:

Qingdao

Brand:

Tianrui

Packaging:

Sealed fiber drum

Price valid (until):

2025-11-12

Contact Supplier

 Chat Now

Hefei Tianrui Pharmaceutical Chemical Co., Ltd.

Company Type:

Manufactory

Location:

China

Payment Terms:

TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average Lead Time:

15 days

Qualification:

Main Products:

APIs

 Visit Store

Product Description
Seller Information

Description

About Product

Garenoxacin (CAS: 194804-75-6) is a high-purity active pharmaceutical ingredient (API) belonging to the novel des-fluoro quinolone class of antibiotics. It demonstrates broad-spectrum activity against Gram-positive and Gram-negative bacteria, particularly effective in treating respiratory tract infections and complicated urinary tract infections. Manufactured by Hefei TianRui Pharmaceutical under strict cGMP conditions, our Garenoxacin API guarantees high purity, excellent stability, and reliable quality for anti-infective formulations.

Items	Specifications
Product Name	Garenoxacin
CAS Registry Number	194804-75-6
IUPAC Name	(‑)-1-(cis-3,5-Dimethylpiperazin-1-yl)-8-ethoxy-9-fluoro-6-fluoro-7-(1-methylaminocycloprop-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
Molecular Weight	458.53 g/mol
Solubility	It is readily soluble in dilute acids, soluble in methanol and slightly soluble in water.
Primary Use	Respiratory tract infection Skin and soft tissue infections Complex urinary tract infection

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 1

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 2

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 3

Company Profile

Founded: 2014
Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology
Facilities:
- Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year
- Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)
- Ultra-low temperature cryogenic reactor (explosion-proof workshop included)
- GMP workshop & clean room
QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

About company

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 7

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

ECHEMI Editorial Reference

ChEBI: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at po ition 7, and a difluoromethoxy group at position 8.Garenoxacin is a new quinolone antimicrobial agent that exhibits a broad spectrum of activity against both Gram-negative and Gram-positive organisms, including the important community-acquired respiratory pathogens S
Garenoxacin is a quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8. It has a role as an antibacterial drug and a non-steroidal anti-inflammatory drug. It is a quinolone antibiotic, a quinolinemonocarboxylic acid, an organofluorine compound, a member of cyclopropanes, an aromatic ether and a member of isoindoles.|Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

Basic Info

Product Name:

Garenoxacin

Other Name:

3-Quinolinecarboxylic acid,1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-;3-Quinolinecarboxylic acid,1-cyclopropyl-8-(difluoromethoxy)-7-(2,3-dihydro-1-methyl-1H-isoindol-5-yl)-1,4-dihydro-4-oxo-,(+)-;1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;Garenoxacin;T 3811;Ganefloxacin;Garenfloxacin;(R)-1-Cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;345632-74-8

CAS No.:

194804-75-6

Molecular Formula:

C23H20F2N2O4

InChIKeys:

InChIKey=NJDRXTDGYFKORP-LLVKDONJSA-N

Molecular Weight:

426.41

Exact Mass:

426.41

UNII:

V72H9867WB

DSSTox ID:

DTXSID30173135

ATC Code:

J - Antiinfectives for systemic use

Categories:

Dermatological Agents

Characteristics

PSA:

78.9

XLogP3:

2.28

Density:

1.421±0.06 g/cm3(Predicted)

Melting Point:

226-227°; mp 234-235°

Boiling Point:

581.5±50.0 °C(Predicted)

Flash Point:

305.5±30.1 °C

Refractive Index:

1.631

Specific rotation:

D27 -9.0° (c = 0.10 in N,N-dimethylformamide)

See More Garenoxacin Properties 

Hazard Identification

Classification of the substance or mixture

no data available

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)	no data available
Signal word	no data available
Hazard statement(s)	no data available
Prevention	no data available
Response	no data available
Storage	no data available
Disposal	no data available

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Garenoxacin Safety Data Sheet 

Seller Information

Business Type:
Manufactory

Main Products:
APIs

Location:
No.23,lntersection of Fenglehe Avenue and Leiyang Road, Huagang Town,Feixi County, Hefei, Anhui, China.

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
15 days

Total Annual Revenue:
$50 million-$100 million

Total Employees:
11-50

Year of Establishment:
2014

About TianRui

Hefei TianRui Pharmaceutical Chemical Co., Ltd was founded in 2014 as a high-tech enterprise focused on the development and industrialization of pharmaceutical small molecule synthesis technology. Our workshop and R&D center are located in Hefei HuaGang Provincial Industrial Park, Anhui Province. We are committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, and functional pharmaceutical excipients and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical companies.

Main Events

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.
Country Product Purchase Quantity Date Posted

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Garenoxacin	/99.00		HANGZHOU LEAP CHEM CO., LTD.	Inquiry
Garenoxacin	/		JHECHEM CO LTD	Inquiry
Garenoxacin cas 194804-75-6	Pharmaceutical Grade/99	$50/MT EXW	Shandong Ailike New Material Technology	Inquiry
Garenoxacin cas 194804-75-6	Pharmaceutical Grade/99		Shandong Airuike Chemical Co., Ltd.	Inquiry
Garenoxacin	/		Chongqing Chemdad	Inquiry

Garenoxacin API - A Broad-Spectrum Quinolone Antibiotic for Bacterial Infections.

Product Description

Seller Information